Allergan and Molecular Partners have expanded an existing partnership with two separate agreements to discover, develop, and commercialize DARPin products for the treatment of serious ophthalmic diseases. Molecular Partners will receive upfront payments of $62.5 million and is eligible to receive additional success-based payments, including as much as $1.4 billion in development, regulatory and sales milestones, and tiered royalties for future product sales.   The first exclusive license agreeme...